TG Therapeutics Reports Record 2025 Revenue & Net Income, Driven by BRIUMVI Sales and Significant Tax Benefit

summarizeSummary

TG Therapeutics reported record 2025 net income of $447.2 million and nearly doubled revenue to $616.3 million, driven by strong BRIUMVI sales and a significant non-cash tax benefit, while advancing its pipeline and authorizing a new $100 million share repurchase program.

check_boxKey Events

• Record Net Income and Revenue Growth

  The company achieved a net income of $447.2 million for 2025, a significant increase from $23.4 million in 2024, with total revenue reaching $616.3 million, nearly double the $329.0 million reported in 2024. Product revenue, primarily from BRIUMVI, grew to $606.9 million from $313.7 million.

• Significant Income Tax Benefit

  A substantial income tax benefit of $339.8 million was recognized in 2025, primarily due to the release of a deferred tax asset valuation allowance, indicating management's positive outlook on future taxable earnings.

• Active Share Repurchase Program

  The previously authorized $100 million share repurchase program was completed in September 2025, with 3,502,334 shares repurchased at an average price of $28.55. A new $100 million share repurchase program was authorized in September 2025, though no repurchases occurred under it in 2025.

• Pipeline Advancement and Strategic Agreements

  Key pipeline updates include the first patient enrollment for ublituximab in myasthenia gravis (January 2025) and azer-cel in progressive multiple sclerosis (August 2025). The Phase 3 pivotal program for subcutaneous ublituximab is approximately 75% enrolled (February 2026). A Strategic Platform License Agreement with MaxCyte was entered into in February 2025 for cell loading technology.

auto_awesomeAnalysis

TG Therapeutics delivered exceptionally strong financial results for 2025, marking a significant turnaround to profitability. The company reported a net income of $447.2 million, a substantial increase from $23.4 million in 2024, primarily driven by robust BRIUMVI sales and a $339.8 million income tax benefit from the release of a deferred tax asset valuation allowance. This tax benefit signals management's increased confidence in sustained future profitability. Product revenue nearly doubled to $606.9 million, reflecting strong market penetration for BRIUMVI in both the U.S. and international markets. The company also continues to advance its pipeline with key milestones, including the first patient enrollment for ublituximab in myasthenia gravis and azer-cel in progressive MS, alongside significant progress in the subcutaneous ublituximab Phase 3 program. The completion of a $100 million share repurchase program and the authorization of a new one underscore a commitment to shareholder returns. Overall, this filing presents a highly positive outlook, demonstrating strong commercial execution and a solid financial foundation for future growth.